

# Cell-free Protein Synthesis

Methods and Protocols

*Edited by*

*Alexander S. Spirin and James R. Swartz*



WILEY-  
VCH

WILEY-VCH Verlag GmbH & Co. KGaA



## **Cell-free Protein Synthesis**

*Edited by*  
*Alexander S. Spirin and*  
*James R. Swartz*

## ***Related Titles***

Budisa, N.

### **Engineering the Genetic Code**

**Expanding the Amino Acid Repertoire for the Design of Novel Proteins**

2006

ISBN 978-3-527-31243-6

Clare, J. J., Trezise, D. J. (eds.)

### **Expression and Analysis of Recombinant Ion Channels**

**From Structural Studies to Pharmacological Screening**

2006

ISBN 978-3-527-31209-2

Gellissen, G. (ed.)

### **Production of Recombinant Proteins**

**Novel Microbial and Eukaryotic Expression Systems**

2005

ISBN 978-3-527-31036-4

Nierhaus, K. H., Wilson, D. N. (eds.)

### **Protein Synthesis and Ribosome Structure**

**Translating the Genome**

2004

ISBN 978-3-527-30638-1

Fischer, R., Schillberg, S. (eds.)

### **Molecular Farming**

**Plant-made Pharmaceuticals and Technical Proteins**

2004

ISBN 978-3-527-30786-9

# Cell-free Protein Synthesis

Methods and Protocols

*Edited by*

*Alexander S. Spirin and James R. Swartz*



WILEY-  
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

## The Editors

### **Professor Dr. Alexander S. Spirin**

Institute of Protein Research  
Russian Academy of Sciences  
142290 Puschchino, Moscow Region  
Russia

### **Professor Dr. James R. Swartz**

Department of Chemical Engineering  
Stauffer III, Rm 113  
Stanford University  
Stanford, CA 94305-5025  
USA

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

### **Library of Congress Card No.:**

applied for

### **British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

### **Bibliographic information published by the Deutsche Nationalbibliothek**

Die Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available in the Internet at <<http://dnb.d-nb.de>>.

© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Typesetting** VTEX, Vilnius, Lithuania

**Printing** betz-druck GmbH, Darmstadt

**Binding** Litges & Dopf GmbH, Heppenheim

**Cover Design** Grafik-Design Schulz, Fußgönheim

Printed in the Federal Republic of Germany  
Printed on acid-free paper

**ISBN:** 978-3-527-31649-6

## Contents

**Preface** XIII

**List of Contributors** XVII

<b>1</b>	<b>Cell-free Protein Synthesis Systems: Historical Landmarks, Classification, and General Methods</b>	<b>1</b>
	<i>A. S. Spirin and J. R. Swartz</i>	
1.1	Introduction: Historical Landmarks	1
1.1.1	Discovery of Protein Synthesis in Cell Extracts	1
1.1.2	Translation of Exogenous Messages	1
1.1.3	Coupled Transcription-translation in Bacterial Extracts	2
1.1.4	Combined Transcription-translation Systems	3
1.1.5	Continuous Flow/Continuous Exchange Principle	3
1.2	Prokaryotic and Eukaryotic Types of Cell-free Expression Systems	5
1.2.1	Cell Extracts	5
1.2.1.1	<i>E. coli</i> extract (ECE)	5
1.2.1.2	Wheat Germ Extract (WGE)	6
1.2.1.3	Rabbit Reticulocyte Lysate (RRL)	6
1.2.2	Genetic Constructs (Expression Vectors)	7
1.2.2.1	Prokaryotic Systems	7
1.2.2.2	Eukaryotic Systems	8
1.3	Preparing Cell Extracts	11
1.3.1	<i>E. coli</i> Extracts	11
1.3.1.1	Genetics	11
1.3.1.2	Cell Growth	13
1.3.1.3	Extract Preparation	14
1.3.2	Wheat Germ Extracts	15
1.4	Designing Reaction Composition	16
1.4.1	Mg <sup>2+</sup> and Phosphate	16
1.4.2	Other Salts	18
1.4.3	Nucleotides and Amino Acids	18
1.4.4	Stabilization Reagents	18

1.4.5	Other Factors	19
1.5	Providing Energy	19
1.5.1	Direct Nucleotide Regeneration	20
1.5.2	Indirect Nucleotide Regeneration	20
1.6	Enhancing Protein Folding	21
1.6.1	Temperature Effects	21
1.6.2	Cell Extract Concentration	23
1.6.3	Effects of Folding Ligands	23
1.6.4	Effects of Chaperones and Foldases	24
1.6.5	Effects of Detergents	24
<b>2</b>	<b>The Constructive Approach for Cell-free Translation</b>	<b>35</b>
	<i>T. Ueda</i>	
2.1	Introduction	35
2.2	The Process of Protein Synthesis	36
2.2.1	Polypeptide Synthesis	36
2.2.2	Protein Maturation	38
2.3	A Constructive Approach to Protein Synthesis	40
2.3.1	<i>In Vitro</i> Reconstitution of Polypeptide Synthesis	40
2.3.2	Protocol of Protein Synthesis using PURE System	41
2.3.3	Addition of Protein Folding Machinery to the PURE System	42
2.3.4	Integration of a Membrane Targeting System with the PURE system	46
2.3.5	Protein Synthesis using the PURE System containing Molecular Chaperones	48
2.4	Conclusion	49
<b>3</b>	<b>Functional Genomic Analysis using Sequential Cell-free Protein Synthesis</b>	<b>51</b>
	<i>K. A. Woodrow and J. R. Swartz</i>	
3.1	Introduction	51
3.1.1	The Post-genomic Era	51
3.1.2	Cell-free Protein Synthesis (CFPS) as a Functional Proteomic Tool	52
3.2	Developing an enabling Technology for Sequential Expression Analysis	54
3.2.1	Improving Linear Template Stability	55
3.2.2	Improving PCR Reactions for generating Genomic Linear Templates	56
3.2.3	Optimizing Cofactor Concentrations for Enzyme Activation	58
3.3	Demonstrating Functional Genomic Analysis with CFPS	61
3.3.1	Isolation and Expression of Genomic Targets	62



3.3.2	Effects of Sample Library on $\beta$ -Lactamase Expression and Activity	62
3.4	Conclusions and Projections	64
<b>4</b>	<b>Cell-free Technology for Rapid Production of Patient-specific Fusion Protein Vaccines</b>	<b>69</b>
	<i>A. R. Goerke, J. Yang, G. Kanter, R. Levy and J. R. Swartz</i>	
4.1	Introduction	69
4.1.1	Lymphoma and Fusion Protein Vaccine Treatments	69
4.1.2	Comparing Cell-free and <i>In Vivo</i> Production Systems	70
4.2	Developing the Fusion Protein Construct and the Cell-free Production Process	71
4.2.1	Fusion-protein Production in the Cell-free System	71
4.2.2	Oxidized Reaction Conditions and DsbC Increase Soluble Protein Yield	71
4.2.3	GM-CSF is more Active at the N-terminus of the Fusion Protein Vaccine	73
4.2.4	New Linker Improves Fusion Protein Stability	75
4.2.5	Expression and Purification Scale-up for Vaccine Protein Production	77
4.3	Fusion Proteins Raise Protective Antibodies	78
4.3.1	Design of Vaccine Constructs and Mouse Studies	78
4.3.2	Fusion Protein Vaccination Protects against Aggressive Tumors	79
4.3.3	Antibody Generation is enhanced by Fusion Partners	79
4.4	Conclusions and Projections	80
<b>5</b>	<b>Bacterial Cell-free System for Highly Efficient Protein Synthesis</b>	<b>83</b>
	<i>T. Kigawa, T. Matsuda, T. Yabuki and S. Yokoyama</i>	
5.1	Overview	83
5.2	Introduction	83
5.3	Coupled Transcription–Translation System based on <i>E. coli</i> Extract	84
5.4	DNA Template Construction	84
5.5	Preparation of Cell Extract from <i>E. coli</i>	85
5.6	Batch-mode Cell-free Reaction	87
5.7	Dialysis-mode Cell-free Reaction	88
5.8	Template DNA	91
5.9	Reaction Temperature	92
5.10	Surface Area of the Dialysis Membrane	93
5.11	Stable-isotope Labeling for NMR Spectroscopy	93
5.12	Selenomethionine Incorporation for X-Ray Crystallography	94
5.13	Automation	95
5.14	Conclusion	95

<b>6</b>	<b>The Use of the <i>Escherichia coli</i> Cell-free Protein Synthesis for Structural Biology and Structural Proteomics</b>	<b>99</b>
	<i>T. Kigawa, M. Inoue, M. Aoki, T. Matsuda, T. Yabuki, E. Seki, T. Harada, S. Watanabe and S. Yokoyama</i>	
6.1	Overview	99
6.2	Introduction	100
6.3	High-throughput Expression by PCR-based Small-scale Cell-free Protein Synthesis	100
6.4	Fully Automated Protein Production using Middle-scale Cell-free Protein Synthesis	103
6.5	NMR Screening	104
6.6	Large-scale Protein Production for Structure Determination	105
6.7	Discussion	107
<b>7</b>	<b>The Wheat Germ Cell-free Protein Synthesis System</b>	<b>111</b>
	<i>T. Sawasaki and Y. Endo</i>	
7.1	Overview	111
7.2	Development of a Highly Efficient Eukaryotic Cell-free Protein Synthesis System	111
7.2.1	Preparation of a Highly Active and Robust Extract from Wheat Embryos	112
7.2.1.1	Protocol for the Preparation of Wheat Germ Extract [12]	115
7.2.2	mRNA 5' and 3' UTRs which Enhance Translation	115
7.2.3	Split-primer PCR for Genome-wide Generation of DNAs for Transcription	119
7.2.3.1	Protocol for "Split-primer" PCR [13]	121
	First PCR	122
7.2.4	Bilayer Translation Reaction Method	122
7.2.5	Transcription and Translation in One Tube	123
7.2.5.1	Protocol for One-tube Protein Synthesis Reaction	124
7.2.6	Reaction Methods for Large-scale Protein Production	125
7.3	Completion of Protocols for the Wheat Cell-free System	126
7.3.1	Performance of the Wheat Cell-free System	127
7.3.2	Robotic Automation of the Cell-free Protein Synthesis	132
7.4	Application to High-throughput Biochemical Annotation of Genetic Information	132
7.4.1	Genome-wide Functional Analysis	132
7.4.2	Preparation of Protein for NMR Spectroscopy	134
7.5	Conclusion	136

<b>8</b>	<b>Cell-free Expression of Integral Membrane Proteins for Structural Studies</b>	<b>141</b>
	<i>C. Klammt, D. Schwarz, I. Lehner, S. Sobhanifar, F. Löhr, J. Zeelen, C. Glaubitz, V. Dötsch and F. Bernhard</i>	
8.1	Overview	141
8.2	Introduction	141
8.3	Specific Characteristics for the Cell-free Expression of Membrane Proteins	143
8.3.1	Cell-free Expression of Membrane Proteins in the Presence of Detergents or Lipids	145
8.3.2	Detergents for the Efficient Resolubilization of Cell-free Produced Membrane Proteins	149
8.4	Case Studies for the High Level Cell-free Expression of Membrane Proteins	150
8.4.1	$\alpha$ -Helical Transporters	150
8.4.2	G-Protein Coupled Receptors	152
8.4.3	$\beta$ -Barrel Proteins	153
8.5	Structural Characterization of Cell-free Produced Membrane Proteins	154
8.5.1	Crystallization of Cell-free Produced Membrane Proteins	154
8.5.2	Cell-free Expression as a Tool for High-resolution NMR Spectroscopy	155
8.5.3	Applications of Cell-free Expression for Solid-state NMR	159
<b>9</b>	<b>Cell-free Production of Membrane Proteins in the Presence of Detergents</b>	<b>165</b>
	<i>J.-M. Betton and M. Miot</i>	
9.1	Introduction	165
9.2	Histidine Protein Kinases	166
9.3	Materials and Methods	168
9.3.1	Plasmids	168
9.3.2	Cell-free Protein Production	168
9.3.3	Protein Purification	168
9.3.4	Structural and Functional Protein Characterizations	169
9.4	Results and Discussion	169
9.4.1	Analytical Cell-free Production of His <sub>6</sub> -tagged Proteins	169
9.4.2	Detergents Compatible with Cell-free Synthesis	171
9.4.3	Fidelity of <i>In Vitro</i> Biosynthesis Reactions in the Presence of Brij35	173
9.4.4	High-level Production of Functional HPKs in CECF Technology	174
9.5	Conclusions	177

<b>10</b>	<b>Novel Techniques using PCR and Cell-free Protein Synthesis Systems for Combinatorial Bioengineering</b>	<b>179</b>
	<i>H. Nakano and T. Yamane</i>	
10.1	Introduction	179
10.2	Improvements in the <i>Escherichia coli</i> Cell-free Protein Synthesis Systems	180
10.3	High-throughput Construction of a Protein Library by SIMPLEX	180
10.3.1	Development of SIMPLEX	180
10.3.2	Quality of the SIMPLEX-based Protein Library	182
10.3.3	Expansion of the SIMPLEX-based Library	182
10.3.4	Application of SIMPLEX for Combinatorial Engineering of Proteins	184
10.4	Development and Application of SICREX	186
10.5	Conclusion	188
<b>11</b>	<b>Gene Cloning and Expression in Molecular Colonies</b>	<b>191</b>
	<i>A. B. Chetverin, T. R. Samatov and H. V. Chetverina</i>	
11.1	A Gap in Cell-free Biotechnology	191
11.2	Molecular Colony Technique	192
11.3	Gene Cloning in Molecular Colonies	193
11.4	Gene Expression in Molecular Colonies: Transcription	196
11.5	Gene Expression in Molecular Colonies: Translation	196
11.6	Gene Expression in Molecular Colonies: The Role of Thiol Compounds	198
11.7	Conclusions	200
11.8	Molecular Colony Protocols	201
11.8.1	Amplification Gels	201
11.8.2	Growing DNA Colonies	202
11.8.3	Detection of Molecular Colonies	202
11.8.4	Transcription in Molecular Colonies	203
11.8.5	Protein Synthesis in Molecular Colonies	203
<b>12</b>	<b>Large-Scale Batch Reactions for Cell-free Protein Synthesis</b>	<b>207</b>
	<i>A. M. Voloshin and J. R. Swartz</i>	
12.1	Introduction	207
12.1.1	Cell-free Protein Synthesis	207
12.1.2	Comparing Cell-free Reaction Configurations; Advantages of Batch Mode	208
12.2	Challenges for Extending Batch Duration and Productivity	210
12.2.1	Providing Energy	210
12.2.2	Stabilizing the Substrates	213
12.3	Scale-up of Reactions not Requiring Oxygen in Batch Mode	216
12.3.1	Test-tube Scale-up Results are Disappointing	216

12.3.2	Thin-film Format Conserves Performance	216
12.3.3	Investigating Fundamental Influences	218
12.4	Scale-up of Reactions Requiring Oxygen	218
12.4.1	Test-tube Scale up is Disastrous	218
12.4.2	Thin-film Format Conserves Performance	222
12.4.3	Stirred Tank Aerated Reactor Format Requires Antifoaming Agents	222
12.4.4	Enhanced O <sub>2</sub> Transfer Increases ATP Concentrations	226
12.4.5	Protein Production in 1-liter Batch Reactions	228
12.5	Conclusions and Projections	231
12.5.1	Personalized Medicine	231
12.5.2	Large-scale Pharmaceutical Production	232
	<b>Index</b>	237



## Preface

We are pleased to offer the following chapters as an update on the rapidly developing field of cell-free protein synthesis (CFPS), a subset of a potentially larger field termed cell-free biology. Although this collection is far from comprehensive, it is intended to provide an overview of the field by offering examples of some of the more exciting developments.

CFPS is a unique embodiment of our fascination with biology and of our desire to harness biology for societal benefit. Early on, agriculture began to harness biology and dramatically changed our social structures by providing plentiful and local food supplies. In more recent times, we industrialized biology. For example, acetone/butanol fermentations helped supply munitions for World War I, and the large scale production of antibiotics saved millions of lives during and after World War II.

But the most dramatic development came with the deciphering of the genetic code and the subsequent ability to reprogram living organisms. While CFPS was instrumental as a research tool in breaking the code, it languished relative to its potential as a protein production tool. Even the breakthrough developments of continuous-flow (CFCF) and continuous-exchange (CECF) operational modes failed to rapidly launch cell-free synthesis as a wide-spread research and production technology. However, over time these developments have combined with the analysis and activation of cell-free metabolism and with a variety of other advances to open exciting new opportunities for the production of complex proteins, for convenient protein evolution, for expanding our knowledge of basic biology, and even for producing complex proteins such as membrane proteins that are very difficult to produce *in vivo*.

In this collection, we first set the stage in Chapter 1 by describing the history of cell-free protein synthesis with emphasis on providing an overview of many of the recent advances. Chapter 2 describes a particularly interesting and powerful development, the use of purified components to catalyze robust protein synthesis. Chapter 3 describes a series of developments that enable CFPS to analyze genomes for those sequences encoding gene products that impact a broad variety of central metabolic processes. Both Chapters 2 and 3 have the potential to provide important new knowledge about protein synthesis and microbial metabolism. They also both provide unique platforms for general protein synthesis.

With Chapter 4, the focus is shifted to a particular application: patient-specific medicine. CFPS offers the speed and economy required when a new protein vaccine is needed for each patient, as is the case for Non-Hodgkins Lymphoma. This chapter describes the development of complex fusion protein vaccines that require the formation of multiple disulfide bonds, but that nevertheless can be rapidly produced by CFPS. Data are also presented to show that these vaccines elicit protective immune responses in mouse tumor models.

Chapter 5 provides new advances in improving the efficiency of CFPS in CECF format using bacterial cell extracts. Chapter 6 then extends that description by showing how these advances provide significant advantages in producing the proteins required for exploring structural biology and structural proteomics.

Although Chapters 2 through 6 describe work with bacterial cell extracts, this is definitely not the only viable approach. Chapter 7 describes the considerable progress made with the use of wheat germ extracts in the CECF format. This eukaryotic system has been used by a variety of laboratories to produce proteins for structural determination as well as for other research applications. An impressive recent achievement of Roche Applied Science group (Penzberg, Germany) in collaboration with GeneCopoeia (Germantown, USSA) and Fulengen (Guangzhou, China) is the expression of 12,000 genes encoding for human proteins using a wheat germ CECF system.

One of the most significant challenges for CFPS has been the production of membrane proteins. Chapters 8 and 9 describe the significant progress made in this pursuit using cell-free methods to avoid the product toxicity that limits *in vivo* production. Chapter 10 then provides impressive examples showing how complex proteins requiring disulfide bonds, special chaperones, and cofactors can be evolved to provide new catalytic function. This is all the more significant since the evolution depends upon single molecule PCR to isolate individual genes and their products in a process termed SIMPLEX (single-molecule PCR-linked *in vitro* expression). With a very interesting alternative approach, Chapter 11 describes the separation, amplification, and cell-free expression of individual DNA molecules within a gel matrix. In this way, the entire process of cloning, expression, and screening of genes and gene libraries can be accomplished without living cells, and, more importantly, in hours instead of days and, potentially, with more complete evaluation of the gene library.

Finally, Chapter 12 addresses technology to enable the cell-free production of proteins at industrial scales and economies. Advances are discussed that allow the relatively efficient use of inexpensive raw materials to dramatically reduce costs. Efficient energy in the form of ATP is supplied by oxidative phosphorylation, but this requires oxygen supply. Thus, methods are also described that allow the use of conventional bioreactors for the large scale, economical cell-free production of proteins.

Taken together, these chapters illustrate the power and versatility of CFPS. Biological evolution has provided an incredible catalog of protein structures and functions. With CFPS, we have the opportunity to directly control the environment in which these polypeptides are produced, folded, and, when appropriate, combined



with other polypeptides. We are freed from the need to maintain cell viability, and we can also channel most, if not all, of the metabolic resources to the production only of our product. We can also design and produce a system of catalysts that will remain relatively invariant over the period of protein production. These considerations suggest that CFPS will be able to produce many proteins that are difficult to produce *in vivo* (as is the case with membrane proteins, for example) and may also be able to produce many proteins more economically than with *in vivo* approaches. For the same reasons, CFPS is developing into an even more powerful research tool. The exciting advances and applications described in this book suggest that CFPS will play an expanding role in modern biotechnology.

July 2007

*Alexander S. Spirin*, Moscow–Pushchino, Russia  
*James A. Swartz*, Stanford, USA



## List of Contributors

### ***Masaaki Aoki***

Protein Research Group  
RIKEN Genomic Sciences Center  
1-7-22 Suehiro-cho Tsurumi  
Yokohama 230-0045  
Japan

### ***Frank Bernhard***

Institute of Biophysical Chemistry  
Centre of Biomolecular Magnetic  
Resonance  
Johann Wolfgang Goethe-University of  
Frankfurt  
Max-von-Laue-Str. 9  
60439 Frankfurt/Main  
Germany

### ***Jean-Michel Betton***

Unité Biochimie Structurale  
Institut Pasteur  
URA-CNRS 2185  
28, rue du Docteur Roux  
75724 Paris cedex 15  
France

### ***Bernd Buchberger***

Roche Diagnostics GmbH  
Roche Applied Science  
R&D Protein Expression  
Nonnenwald 2  
82372 Penzberg  
Germany

### ***Alexander B. Chetverin***

Institute of Protein Research  
Russian Academy of Sciences  
Pushchino  
Moscow Region 142290  
Russia

### ***Helena V. Chetverina***

Institute of Protein Research  
Russian Academy of Sciences  
Pushchino  
Moscow Region 142290  
Russia

### ***Volker Dötsch***

Institute of Biophysical Chemistry  
Centre of Biomolecular Magnetic  
Resonance  
Johann Wolfgang Goethe-University of  
Frankfurt  
Max-von-Laue-Str. 9  
60439 Frankfurt/Main  
Germany

### ***Yaeta Endo***

Cell-Free Science and  
Technology Research Center  
Ehime University  
Matsuyama, Ehime 790-8577  
Japan

**Clemens Glaubitz**

Institute of Biophysical Chemistry  
Centre of Biomolecular Magnetic  
Resonance  
Johann Wolfgang Goethe-University of  
Frankfurt  
Max-von-Laue-Str. 9  
60439 Frankfurt/Main  
Germany

**Aaron R. Goerke**

Department of Chemical Engineering  
Stanford University  
Stanford  
California 94305  
USA

**Takushi Harada**

Protein Research Group  
RIKEN Genomic Sciences Center  
1-7-22 Suehiro-cho Tsurumi  
Yokohama 230-0045  
Japan

**Makoto Inoue**

Protein Research Group  
RIKEN Genomic Sciences Center  
1-7-22 Suehiro-cho Tsurumi  
Yokohama 230-0045  
Japan

**Gregory Kanter**

Department of Medicine  
Division of Oncology  
Stanford University  
Stanford University Medical Center  
Stanford  
California 94305  
USA

**Takanori Kigawa**

Protein Research Group  
RIKEN Genomic Sciences Center  
1-7-22 Suehiro-cho Tsurumi  
Yokohama 230-0045  
Japan

**Christian Klammt**

Institute of Biophysical Chemistry  
Centre of Biomolecular Magnetic  
Resonance  
Johann Wolfgang Goethe-University of  
Frankfurt  
Max-von-Laue-Str. 9  
60439 Frankfurt/Main  
Germany

**Ines Lehner**

Institute of Biophysical Chemistry  
Centre of Biomolecular Magnetic  
Resonance  
Johann Wolfgang Goethe-University of  
Frankfurt  
Max-von-Laue-Str. 9  
60439 Frankfurt/Main  
Germany

**Ronald Levy**

Department of Medicine  
Division of Oncology  
Stanford University  
Stanford University Medical Center  
Stanford  
California 94305  
USA

**Frank Löhr**

Institute of Biophysical Chemistry  
Centre of Biomolecular Magnetic  
Resonance  
Johann Wolfgang Goethe-University of  
Frankfurt  
Max-von-Laue-Str. 9  
60439 Frankfurt/Main  
Germany

**Kairat Madin**

Roche Diagnostics GmbH  
Roche Applied Science  
R&D Protein Expression  
Nonnenwald 2  
D-82372 Penzberg  
Germany

**Takayoshi Matsuda**

Protein Research Group  
RIKEN Genomic Sciences Center  
1-7-22 Suehiro-cho Tsurumi  
Yokohama 230-0045  
Japan

**Marika Miot**

Unité Biochimie Structurale  
Institut Pasteur  
URA-CNRS 2185  
28, rue du Docteur Roux  
75724 Paris cedex 15  
France

**Hideo Nakano**

Laboratory of Molecular Biotechnology  
Graduate School of Bioagricultural  
Sciences  
Nagoya University  
Furo-cho, Chikusa-ku  
Nagoya 464-8601  
Japan

**Timur R. Samatov**

Institute of Protein Research  
Russian Academy of Sciences  
Pushchino  
Moscow Region 142290  
Russia

**Tatsuya Sawasaki**

Cell-Free Science and Technology  
Research Center  
Ehime University  
Matsuyama 790-8577  
Japan

**Daniel Schwarz**

Institute of Biophysical Chemistry  
Centre of Biomolecular Magnetic  
Resonance  
Johann Wolfgang Goethe-University of  
Frankfurt  
Max-von-Laue-Str. 9  
60439 Frankfurt/Main  
Germany

**Alexander S. Spirin**

Institute of Protein Research  
Russian Academy of Sciences  
Puschchino  
Moscow Region 142290  
Russia

**James R. Swartz**

Departments of Chemical Engineering  
and BioEngineering  
Stanford University  
Stanford  
California 94305-5025  
USA

**Eiko Seki**

Protein Research Group  
RIKEN Genomic Sciences Center  
1-7-22 Suehiro-cho Tsurumi  
Yokohama 230-0045  
Japan

**Solmaz Sobhanifar**

Institute of Biophysical Chemistry  
Centre of Biomolecular Magnetic  
Resonance  
Johann Wolfgang Goethe-University of  
Frankfurt  
Max-von-Laue-Str. 9  
60439 Frankfurt/Main  
Germany

**Takuya Ueda**

Department of Medical Genome  
Sciences  
Graduate School of Frontier Sciences  
The University of Tokyo  
5-1-5 Kashiwanoha, Kashiwa  
Chiba Prefecture 277-8562  
Japan

**Alexei M. Voloshin**

Departments of Chemical Engineering  
Stanford University  
Stanford  
California 94305-5025  
USA

***Satoru Watanabe***

Protein Research Group  
RIKEN Genomic Sciences Center  
1-7-22 Suehiro-cho Tsurumi  
Yokohama 230-0045  
Japan

***Kim A. Woodrow***

Department of Chemical Engineering  
Stanford University  
Stanford  
California 94305-5025  
USA

***Tsuneo Yamane***

College of Bioscience and Biotechnology  
Chubu University  
Matsumoto-cho 1200, Kasugai  
Aichi 487-8501  
Japan

***Takashi Yabuki***

Protein Research Group  
RIKEN Genomic Sciences Center  
1-7-22 Suehiro-cho Tsurumi  
Yokohama 230-0045  
Japan

***Junhao Yang***

Department of Chemical Engineering  
Stanford University  
Stanford  
California 94305  
USA

***Shigeyuki Yokoyama***

Protein Research Group  
RIKEN Genomic Sciences Center  
1-7-22 Suehiro-cho Tsurumi  
Yokohama 230-0045  
Japan

***Johan Zeelen***

Max-Planck-Institute of Biophysics  
Department for Structural Biology  
Max-von-Laue-Str. 3  
60438 Frankfurt am Main  
Germany

# 1

## Cell-free Protein Synthesis Systems: Historical Landmarks, Classification, and General Methods

Alexander S. Spirin and James R. Swartz

### 1.1

#### Introduction: Historical Landmarks

##### 1.1.1

#### Discovery of Protein Synthesis in Cell Extracts

The demonstration of the capability of disintegrated cells and cell extracts to continue protein synthesis was among the great discoveries of the early 1950s that led to the birth of molecular biology. The original observations were made independently in several laboratories working with homogenates and homogenate fractions of animal tissues [16, 132, 154, 155, 174, 175]. Shortly afterwards, disrupted bacterial cells were also shown to be capable of synthesizing proteins [42] and the fraction of ribonucleoprotein particles called ribosomes was identified as the heart of the protein-synthesizing machinery of the cell [138]. Cell extracts freed from heavy components by centrifugation at 30000g (the so-called S30 extracts) and supplemented with amino acids, ATP and GTP, were the first cell-free protein-synthesizing systems [65, 95, 99, 100, 114, 137, 148, 168].

In those systems, however, the ribosomes just continued to translate endogenous mRNAs and elongate the polypeptides for which synthesis had already been started. Nevertheless, a high level of globin synthesis from endogenous mRNA templates could be achieved using rabbit reticulocyte lysates, and several general molecular mechanisms of protein-synthesizing machinery were studied (see, e.g., Refs. [54, 135]).

##### 1.1.2

#### Translation of Exogenous Messages

The principal breakthrough in the development of cell-free protein-synthesizing systems was made in 1961 when Nirenberg and Matthaei managed to destroy endogenous mRNA in the bacterial (*E. coli*) extract without damaging ribosomes and the rest of the protein-synthesizing machinery [124, 125]. The ribosome run-off and the selective destruction of endogenous mRNAs was accomplished by a simple pro-

cedure of pre-incubation of the extract at 30–37 °C. The introduction of polyribonucleotides in such mRNA-depleted extracts resulted in effective *translation of exogenous messages*. The experiments with translation of synthetic polyribonucleotides, such as poly(U), poly(A), poly(C) and random copolymers poly(U,C), poly(U,C,A), etc., deciphered the genetic code. Furthermore, natural alien messages, including eukaryotic mRNAs, could be successfully expressed in such bacterial extracts.

Later, addition of a  $\text{Ca}^{2+}$ -dependent micrococcal ribonuclease with subsequent inactivation of the enzyme by removal of  $\text{Ca}^{2+}$  with EGTA was used for destruction of endogenous globin mRNA in the reticulocyte lysate [130]. Such mRNA-depleted animal extracts became the basis of the most efficient eukaryotic cell-free systems [55, 57, 115].

Another type of eukaryotic cell-free system was based on wheat germ extracts [106, 136]. In this case the content of active endogenous mRNA in the extract was found to be so low that there was no need for the pre-treatment procedures described above [5, 105].

### 1.1.3

#### **Coupled Transcription-translation in Bacterial Extracts**

In the case of bacterial cell-free translation systems, the addition of pre-synthesized mRNA to a cell extract violates the principle of natural prokaryotic translation. In prokaryotic cells, translation of a mRNA by ribosomes is initiated soon after the beginning of its synthesis on the DNA template. The ribosomes move along mRNA chain not far behind the RNA polymerase, and both processes proceed with synchronized rates (*coupled transcription-translation*) [102, 181]. When pre-synthesized, complete mRNAs are used in cell-free translation systems, the initiation of translation sometimes may be hindered by mRNA folding and tertiary structure formation, especially if ribosome-binding sites are involved.

The first demonstration of DNA-dependent incorporation of amino acids into synthesized proteins as well as the first evidence for the coupled transcription-translation process in bacterial cell-free systems were also made by Nirenberg's group in the beginning of the 1960s [21, 110]. In 1967, Zubay and colleagues made significant improvements [36, 97] and introduced an efficient bacterial coupled transcription-translation system for expression of exogenous DNA [27, 189]. Their system was based on crude cell-free *E. coli* extract containing endogenous RNA polymerase, but devoid of endogenous DNA and mRNA due to exhaustive nuclease degradation. This improved method was broadly adopted, although somewhat modified protocols were reported by others (see, e.g., Ref. [134]).

Another practical version of the bacterial coupled transcription-translation system for exogenous gene expression was proposed by Gold and Schweiger [49, 50, 149], who used the mixture of isolated *E. coli* ribosomes, tRNA and ribosome-free supernatant (the so-called S100 extract) purified by ion-exchange chromatography from all nucleic acids, instead of the crude extract with degraded nucleic acids.



## 1.1.4

**Combined Transcription-translation Systems**

The next important step in the development of cell-free gene expression was the combination of a cell extract with a specific bacteriophage RNA polymerase that used a phage-specific promoter for transcription. Either SP6 polymerase [161] or T7 polymerase [30, 123] were suggested for such cell-free systems. These polymerases direct the exclusive synthesis of the proteins encoded by genes preceded by the corresponding phage promoters. Such systems possess several advantages: (a) the phage polymerases provide a higher level of transcripts than endogenous bacterial RNA polymerase; (b) the addition of rifampicin selectively inhibits the endogenous RNA polymerase, and thus there is no need to self-digest or treat cell extract for removal of endogenous DNA; (c) due to the promoter specificity of the phage RNA polymerase, only the gene of interest is expressed; (d) the systems are convenient for expression from any plasmid constructs and PCR products where the simple phage promoters are inserted; and (e) the phage RNA polymerases and DNA templates with phage promoters can be combined both with prokaryotic [123, 161] and eukaryotic [30, 161] extracts.

Strictly speaking, these systems cannot be referred to as “coupled transcription-translation” systems: both spatial and temporal coupling is absent in this case because the T7 and SP6 RNA polymerases work much faster than the endogenous bacterial polymerase and translation machinery, the transcripts quickly accumulate in excess over translating ribosomes, and thus mRNA is synthesized mainly in advance in such systems. The term “combined transcription-translation” is a more appropriate designation. It should be mentioned that both purified *E. coli* RNA polymerase [18, 28, 98, 137, 164] and animal virus-associated RNA polymerases [7, 29, 131] were also used in the combined cell-free transcription-translation systems based on eukaryotic extracts, but the use of SP6 and T7 phage polymerases proved to be the most successful.

## 1.1.5

**Continuous Flow/Continuous Exchange Principle**

In cell-free translation and transcription-translation systems performed in a fixed volume of a test-tube (batch format) the reaction conditions change during incubation as a result of the consumption of substrates and the accumulation of products. Translation stops as soon as any essential substrate is exhausted or any product or by-product reaches an inhibiting concentration, usually after 20–60 minutes of incubation. The limited lifetimes and, as a consequence, low yields of protein products made the early batch systems useful mainly for analytical purposes and inappropriate for preparative synthesis of polypeptides and proteins.

A principal breakthrough was the invention of the so-called *continuous-action* or *continuous-duty* translation [4, 160] and transcription-translation systems [8, 10] (see also Refs. [14, 15, 153, 161, 162]). Instead of incubating the reaction mixture in a fixed volume in a test-tube, the reaction was performed under conditions of *per-*

*sistent supply* of the consumable substrates (amino acids, nucleoside triphosphates and energy-regenerating compounds) and with *removal* of the reaction products (mainly inorganic phosphates and nucleoside monophosphates, as well as polypeptide products and by-products in some reactor versions). To achieve that, a porous (ultrafiltration or dialysis) membrane was used to retain the high-molecular-weight components of the protein-synthesizing machinery (ribosomes, mRNA, ARSases, etc.) within a defined reaction compartment. The membrane separated the reaction compartment from another compartment containing a feeding solution with a reservoir of low-molecular-weight components (substrates) for the reaction. This technique was reproduced in a number of laboratories [37, 38, 66, 90, 126, 127, 171, 172, 177].

In so-called continuous-flow cell-free (CFCF) systems [8, 10, 160] the feeding solution with substrates is continuously pumped into the chamber containing the reaction mixture, and the products are continuously removed through the ultrafiltration membrane by the outgoing flow. Reactors working in pulsating [161] (see also Ref. [162]) or “discontinuous” (see Chapter 7 of this book) modes, with alternating flow-in and flow-out instead of the direct continuous flow, can also be used.

In the dialysis format of the continuous systems, designated also as continuous-exchange cell-free (CECF) systems, the passive (diffusional) exchange of substrates and low-molecular-weight products through a porous barrier takes place [4, 26, 107, 153, 162]. The dialysis (CECF) format was found to be much simpler and more practical than the CFCF format, and became the most widely exploited type of the continuous-action cell-free systems in laboratories (see Refs. [67, 70, 79, 103, 145] and Chapters 5–9), as well as in commercialized technologies (see, e.g., Refs. [13, 33, 34, 108]). Both simple dialysis bags and reactors with flat dialysis membranes are used. The reactors with hollow fibers were also proposed [161, 177]. Notably, the same continuous-exchange principle can be realized also without a dialysis membrane. Reactors have been proposed where the diffusional product/substrate exchange is accomplished between gel capsules that hold the protein-synthesizing mixture and the outside feeding solution [161]. Other formats include the use of Sephadex granules to retain the feeding solution while the reaction mixture occupies the inter-granule space [17], and a configuration in which the reaction mixture and feeding solution exist in two liquid layers separated only by a phase boundary [146] (see also Ref. Chapter 7).

The use of the continuous-action principle in cell-free translation and transcription-translation systems maintains more or less constant reaction conditions and prolongs the active working time of the systems up to many hours or even days. As a result, the yield of the product increased to milligrams of protein per mL of incubation mixture.